Exposure‐response Analysis for Spontaneously Reported Dizziness in Pregabalin‐treated Patient With Generalized Anxiety Disorder
暂无分享,去创建一个
R. Miller | B. Frame | R Miller | M. Hutmacher | K Ito | Mm Hutmacher | J Liu | R Qiu | B Frame | K. Ito | R. Qiu | J. Liu
[1] T. Pugsley,et al. Stimulus-dependent modulation of [(3)H]norepinephrine release from rat neocortical slices by gabapentin and pregabalin. , 2000, The Journal of pharmacology and experimental therapeutics.
[2] J. Offord,et al. The Novel Anticonvulsant Drug, Gabapentin (Neurontin), Binds to the Subunit of a Calcium Channel (*) , 1996, The Journal of Biological Chemistry.
[3] L B Sheiner,et al. Quantitative characterization of therapeutic index: Application of mixed‐effects modeling to evaluate oxybutynin dose–efficacy and dose–side effect relationships , 1999, Clinical pharmacology and therapeutics.
[4] E. Perucca,et al. Progress report on new antiepileptic drugs: a summary of the fourth Eilat conference (EILAT IV) , 1999, Epilepsy Research.
[5] H. Clusmann,et al. Inhibition of neuronal Ca2+ influx by gabapentin and pregabalin in the human neocortex , 2002, Neuropharmacology.
[6] A. McKnight,et al. Gabapentin inhibits the substance P-facilitated K+-evoked release of [3H]glutamate from rat caudal trigeminal nucleus slices , 2001, Pain.
[7] D R Stanski,et al. Population pharmacodynamic model for ketorolac analgesia , 1996, Clinical pharmacology and therapeutics.
[8] S. Borosky,et al. Inhibition of K+-evoked glutamate release from rat neocortical and hippocampal slices by gabapentin , 2000, Neuroscience Letters.
[9] Lynn McFadyen,et al. A Two-Part Mixture Model for Longitudinal Adverse Event Severity Data , 2003, Journal of Pharmacokinetics and Pharmacodynamics.
[10] D. Welty,et al. Pharmacokinetics and pharmacodynamics of CI-1008 (pregabalin) and gabapentin in rats with maximal electroshock , 1977 .